サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：骨髄異形成症候群（MDS）治療薬の世界市場-2023-2030
市場調査レポート
商品コード
1290358

骨髄異形成症候群（MDS）治療薬の世界市場-2023-2030

Global Myelodysplastic Syndrome (MDS) Treatment Market - 2023-2030

出版日
ページ情報
英文 195 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
骨髄異形成症候群（MDS）治療薬の世界市場-2023-2030
出版日: 2023年06月12日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

市場概要

骨髄異形成症候群（MDS）治療の世界市場は、2022年に30億6,550万米ドルに達し、2030年には最大60億5,950万米ドルに達することで有利な成長が予測されます。世界の骨髄異形成症候群治療市場は、予測期間（2023年～2030年）に9.1%のCAGRを示すと予測されています。

幹細胞移植は、世界の骨髄異形成症候群治療市場を牽引する大きな動向の1つです。骨髄異形成症候群患者の根治的な治療オプションである造血幹細胞移植（HSCT）も研究開発の対象になっています。移植の成功に影響を与える要因であるドナー選択、コンディショニングレジメン、移植片対宿主病予防技術などは、研究によってより深く理解されるようになりました。

さらに、骨髄異形成症候群に対する免疫療法の開発も研究開発の一つです。この治療法は、体の免疫システムを利用して、悪性細胞や病気の細胞を見つけ、破壊するものです。例えば、ペムブロリズマブなどの免疫チェックポイント阻害剤は、特定の遺伝子変異を持つMDS患者のサブセットで有望視されています。予想される期間中、骨髄異形成症候群（MDS）治療市場の成長を促進すると考えられます。

市場力学

研究開発の進展が骨髄異形成症候群治療市場の成長を促進する

研究開発の進歩は、骨髄異形成症候群治療の分野における進歩や革新を促進する上で重要な役割を担っています。研究開発の努力により、骨髄異形成症候群の根底にある分子メカニズムに対する研究者の理解が深まっています。これには、骨髄異形成症候群の発症と進行に寄与する特定の遺伝子変異や異常の特定が含まれます。

先進的なゲノム解析技術により、骨髄異形成症候群の遺伝的背景を明らかにすることができ、より正確な診断と標的治療が可能になりました。

2022年にJournal of Hematology and Oncology誌に掲載された論文によると、MDSの分子および遺伝的特徴が明らかになったことで、この病気の発症メカニズムがより理解され、真新しい治療法の創出も加速しています。さまざまな血液悪性腫瘍は、標的治療や免疫治療によく反応するようになりました。

メチル化阻害剤（HMA）の導入は、MDS、特にハイリスクMDSの管理における注目すべき進歩の一つです。歴史的なランダム化試験であるAZA-001試験では、アザシチジン（AZA）がOS中央値を従来の治療法の15ヶ月から約24ヶ月に大幅に伸ばしました。このような統計から、ハイリスクMDS患者の治療にはAZAが標準的に採用されるようになりました。

骨髄異形成症候群治療に伴う副作用が、予測期間における世界の骨髄異形成症候群治療市場の成長を阻害しています

化学療法や免疫抑制療法などの骨髄異形成症候群治療には、重大な副作用が生じる可能性があります。これらの副作用は、患者のQOLに影響を与え、治療レジメンを遵守する上で課題となることがあります。

副作用には、咳や息切れ、胃痙攣や便秘、新たな発疹、皮膚の赤み、かゆみ、そして持続的な頭痛、体のどこにでもある新たな痛みや痛みなどがあります。

さらに、化学療法薬や造血幹細胞移植などの骨髄異形成症候群の治療には、高額な費用がかかることがあります。治療費が高額なため、十分な保険が適用されない患者さんや経済的に余裕のない患者さんは、治療へのアクセスが制限される可能性があります。

COVID-19の影響分析

COVID-19の流行は、骨髄異形成症候群治療市場に大きな影響を与えています。2022年4月にLeukemia誌に掲載された論文によると、COVID-19は、急性白血病、高リスク骨髄異形成症候群、造血細胞移植やキメラ抗原受容体T治療後の血液疾患患者における死亡率の有意差と関連していることが判明しています。

重症度や予後は悪くなるもの、臨床症状や徴候は一般住民の報告と同様でした。2023年現在、COVID-19の状況は回復しており、患者はすべてのヘルスケア施設にアクセスできるため、骨髄異形成症候群治療市場の世界の需要増加につながります。

ロシア・ウクライナ紛争分析

ロシア・ウクライナ紛争が骨髄異形成症候群治療市場に与える影響は複雑で多面的です。地政学的な不安定さや経済的な不確実性のある時代には、疾病の負担やヘルスケア施設に影響が出る可能性があります。その結果、骨髄異形成症候群の治療に対する需要が減少し、治療オプションにアクセスしにくくなる可能性があります。

紛争により、骨髄異形成症候群の治療に関する研究開発活動から資源や注意が遠のく可能性があります。被災地の製薬会社や研究機関は、臨床試験の実施、データの収集、新規治療法の開発において困難に直面する可能性があります。

紛争の影響を直接受けた地域では、ヘルスケア関係者や患者が移動し、骨髄異形成症候群の治療サービスが中断される可能性があります。患者がヘルスケア施設にアクセスすることが困難となり、診断や治療開始の遅れにつながる可能性があります。

目次

第1章 調査手法とスコープ

  • 調査手法
  • 調査目的および調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

  • 治療タイプ別スニペット
  • エンドユーザー別
  • 地域別スニペット

第4章 市場力学

  • 影響要因
    • 促進要因
      • 骨髄異形成症候群の人口増加
    • 抑制要因
      • 薬物療法に伴う副作用
    • 機会
      • 骨髄異形成症候群治療薬の研究開発
    • 影響分析

第5章 産業分析

  • ポーターの5フォース分析
  • サプライチェーン分析
  • アンメットニーズ
  • 法規制分析

第6章 COVID-19の分析

  • COVID-19の分析
    • COVID-19の前のシナリオ
    • COVID-19期間中のシナリオ
    • COVID-19後のシナリオ
  • COVID-19の中での価格・ダイナミクス
  • 需給スペクトル
  • パンデミック時の市場に関連する政府の取り組み
  • メーカー別戦略的な取り組み
  • サマリー

第7章 ロシア・ウクライナ戦争分析

第8章 人工知能の分析

第9章 治療タイプ別

  • 幹細胞移植
  • 免疫治療
  • 化学療法
    • ハイポメチル化剤
      • アザシチジン（ビダザ）
      • デシタビン（ダコゲン）
  • 免疫調節薬
    • レナリドマイド（レブリミド）
    • その他
  • 抗悪性腫瘍剤
    • ラスパテルセプト（REBLOZYL）
    • その他
  • その他
    • シタラビン（シトサル-U）
    • ダウノルビシン（セルビジン）
    • イダルビシン（イダマイシン）
    • INQOVI (ASTX727)

第10章 エンドユーザー別

  • 病院
  • 専門クリニック
  • その他エンドユーザー

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第12章 競合情勢

  • 競合シナリオ
  • 製品ベンチマーク
  • 企業シェア分析
  • 主な発展と戦略

第13章 企業プロファイル

  • AbbVie Inc.
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展状況
  • Accord Healthcare
  • Bristol-Myers Squibb
  • Jazz Pharmaceuticals Inc.
  • Novartis AG
  • Lupin Pharmaceuticals
  • Otsuka America Pharmaceutical Inc.
  • Onconova Therapeutics
  • Takeda Pharmaceutical Company Limited
  • Astex Pharmaceuticals, Inc.

第14章 付録

目次
Product Code: PH2678

Market Overview

The Global Myelodysplastic Syndrome (MDS) Treatment Market reached US$ 3,065.5 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 6,059.5 million by 2030. The global myelodysplastic syndrome treatment market is expected to exhibit a CAGR of 9.1% during the forecast period (2023-2030).

Stem cell transplantation is one of the major trends driving the global myelodysplastic syndrome treatment market. A curative therapeutic option for myelodysplastic syndrome patients, hematopoietic stem cell transplantation (HSCT), has also been the subject of R&D work. The factors influencing transplantation success, such as donor selection, conditioning regimens, and graft-versus-host disease preventive techniques, have been better understood via research.

Furthermore, the development of immunotherapies for myelodysplastic syndrome is another area of research and development. These treatments use the immune system of the body to find and destroy malignant or sick cells. For instance, immune checkpoint inhibitors, such as pembrolizumab, have shown promise in subsets of MDS patients with specific genetic mutations. estimated to fuel the growth of the Myelodysplastic Syndrome (MDS) Treatment market throughout the anticipated time frame.

Market Dynamics

Advancements in Research and Development are Boosting the Global Myelodysplastic Syndrome Treatment Market Growth

Advancements in research and development (R&D) have played a significant role in driving progress and innovation in the field of myelodysplastic syndrome treatment. R&D efforts have deepened researchers' understanding of the molecular mechanisms underlying myelodysplastic syndrome. This includes identifying specific genetic mutations and abnormalities that contribute to the development and progression of the disease.

Through advanced genomic sequencing techniques, researchers have been able to characterize the genetic landscape of MDS, allowing for more precise diagnosis and targeted treatment approaches.

As per the article published in the Journal of Hematology and Oncology in 2022, the pathogenesis of the disease has been better understood because of the molecular and genetic characterization of MDS, which has also sped up the creation of brand-new treatments. Different hematologic malignancies have responded well to targeted and immune treatments.

The introduction of hypomethylating drugs (HMAs) is one of the noteworthy advancements in the management of MDS, particularly high-risk-MDS. In the historic randomized AZA-001 trial, azacitidine (AZA) considerably increased the median OS from 15 months with conventional treatments to about 24 months. These statistics have led to the adoption of AZA as the norm for treating individuals with high risk-MDS.

Side Effects Associated with Myelodysplastic Syndrome Treatment are Hampering the Global Myelodysplastic Syndrome Treatment Market Growth in the Forecast Period.

Myelodysplastic syndrome treatments, such as chemotherapy or immunosuppressive therapy, can have significant side effects. These side effects may impact the patient's quality of life and pose challenges in adhering to the treatment regimen.

The side effects include coughing or shortness of breath, stomach cramps or constipation, a new rash, reddening of the skin, itching, and a persistent headache, new pain or soreness anywhere on the body.

In addition, myelodysplastic syndrome treatments, such as chemotherapy drugs or hematopoietic stem cell transplantation, can be expensive. The high cost of treatment may limit access for patients who do not have adequate insurance coverage or financial resources.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the myelodysplastic syndrome treatment market. According to the article published in Leukemia in April 2022, COVID-19 has been linked to a significant mortality rate in hematological patients with acute leukemia, high-risk myelodysplastic syndromes, and following hematopoietic cell transplant and chimeric antigen receptor T treatments.

Although the severity and prognosis were worse, the clinical symptoms and signs were similar to those reported for the general population. As of 2023, the COVID-19 situation is recovering and patients can access all healthcare facilities leading to an increasing demand for the myelodysplastic syndrome treatment market worldwide.

Russia-Ukraine Conflict Analysis

The impact of the Russia-Ukraine war on the myelodysplastic syndrome treatment market is complex and multifaceted. In times of geopolitical instability and economic uncertainty, the burden of disease and healthcare facilities can be affected. This can result in a lack of accessibility of treatment options resulting in decreased demand for treatment of the myelodysplastic syndrome.

The conflict may divert resources and attention away from research and development activities related to myelodysplastic syndrome treatments. Pharmaceutical companies and research institutions in the affected regions may face challenges in conducting clinical trials, collecting data, and advancing novel therapies.

In regions directly affected by the conflict, healthcare professionals and patients may be displaced, resulting in the disruption of myelodysplastic syndrome treatment services. Patients may have difficulty accessing healthcare facilities, leading to delays in diagnosis and treatment initiation.

Segment Analysis

The global myelodysplastic syndrome treatment market is segmented based on treatment type, end-user, and region.

The Stem Cell Transplant Segment is Expected to Hold a Dominant Position in the Market Over the Forecast Period

The stem cell transplant segment accounted for the highest market stake accounting for approximately 27.3% of the myelodysplastic syndrome treatment market. Patients with myelodysplastic syndromes may benefit from stem cell transplantation as a treatment.

An allogeneic stem cell transplant and an autologous stem cell transplant are the two main varieties of SCT. After the patient's bone marrow is removed during an allogeneic stem cell transplant, the donor's blood-forming stem cells are given to the patient. This kind of transplant is frequently utilized for MDS.

The patient's own stem cells, which were extracted prior to therapy, are given back during an autologous stem cell transplant. Patients with myelodysplastic syndrome are often not candidates for this sort of transplant because their bone marrow includes aberrant stem cells.

The only treatment available today that can induce long-lasting remission is high-dose chemotherapy combined with a bone marrow/stem cell transplant. However, because transplantation carries a higher risk of side effects, it may not be suggested for people who are older or have additional health issues.

An allogeneic transplant, however, might be an option for people between the ages of 50 and 75 after less intense therapy. The surgeon will discuss the risks of transplantation in detail before recommending it. They will also take into account the age and general health, the subtype of myelodysplastic syndrome, the outcomes of any prior treatments, and many other things.

Geographical Analysis

Increasing Research and Development and Advancement in Myelodysplastic Syndrome Treatment Dominate the North American Region

North America is expected to dominate the myelodysplastic syndrome treatment market, accounting for around 41.6% of this market. In December 2022, Arcellx, Inc., a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, announced the start of Phase 1 clinical trial of ACLX-002 for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes, as well as the continuation of robust long-term responses from its CART-ddBCMA Phase 1 expansion trial in patients with relapsed or refractory multiple myeloma.

Furthermore, in December 2022, Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, presented at the 64th American Society of Haematology (ASH) Annual Meeting and Exposition encouraging Phase 1 dose escalation data from the current Phase 1/1b clinical research of PRGN-3006 UltraCAR-T in patients with r/r AML and higher risk myelodysplastic syndromes.

Competitive Landscape

The major global players in the market include: AbbVie Inc., Accord Healthcare, Bristol-Myers Squibb, Jazz Pharmaceuticals Inc., Novartis AG, Lupin Pharmaceuticals, Otsuka America Pharmaceutical Inc., Onconova Therapeutics, Takeda Pharmaceutical Company Limited, and Astex Pharmaceuticals, Inc. among others.

Why Purchase the Report?

  • To visualize the global myelodysplastic syndrome treatment market segmentation based on the treatment type, end-user, and region and understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of myelodysplastic syndrome treatment market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global myelodysplastic syndrome treatment market report would provide approximately 54 tables, 50 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Treatment Type
  • 3.2. Snippet by End User
  • 3.3. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing population with myelodysplastic syndrome
    • 4.1.2. Restraints
      • 4.1.2.1. Side effects associated with the medications
    • 4.1.3. Opportunity
      • 4.1.3.1. Research and development of myelodysplastic syndrome drugs
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Unmet Needs
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Artificial Intelligence Analysis

9. By Treatment Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.1.2. Market Attractiveness Index, By Treatment Type
  • 9.2. Stem Cell Transplant*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Immune Treatments
  • 9.4. Chemotherapy
    • 9.4.1. Hypomethylating Agents
      • 9.4.1.1. Azacitidine (Vidaza)
      • 9.4.1.2. Decitabine (Dacogen)
  • 9.5. Immunomodulatory Drugs
    • 9.5.1. Lenalidomide (Revlimid)
    • 9.5.2. Others
  • 9.6. Anti-anemics
    • 9.6.1. Luspatercept-aamt (REBLOZYL)
    • 9.6.2. Others
  • 9.7. Others
    • 9.7.1. Cytarabine (Cytosar-U)
    • 9.7.2. Daunorubicin (Cerubidine)
    • 9.7.3. Idarubicin (Idamycin)
    • 9.7.4. INQOVI (ASTX727)

10. By End User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.1.2. Market Attractiveness Index, By End User
  • 10.2. Hospitals*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Specialty Clinics
  • 10.4. Other End Users

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.5.1. The U.S.
      • 11.2.5.2. Canada
      • 11.2.5.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.5.1. Germany
      • 11.3.5.2. The U.K.
      • 11.3.5.3. France
      • 11.3.5.4. Italy
      • 11.3.5.5. Spain
      • 11.3.5.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.5.1. Brazil
      • 11.4.5.2. Argentina
      • 11.4.5.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.5.1. China
      • 11.5.5.2. India
      • 11.5.5.3. Japan
      • 11.5.5.4. Australia
      • 11.5.5.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Product Benchmarking
  • 12.3. Company Share Analysis
  • 12.4. Key Developments and Strategies

13. Company Profiles

  • 13.1. AbbVie Inc.*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Accord Healthcare
  • 13.3. Bristol-Myers Squibb
  • 13.4. Jazz Pharmaceuticals Inc.
  • 13.5. Novartis AG
  • 13.6. Lupin Pharmaceuticals
  • 13.7. Otsuka America Pharmaceutical Inc.
  • 13.8. Onconova Therapeutics
  • 13.9. Takeda Pharmaceutical Company Limited
  • 13.10. Astex Pharmaceuticals, Inc.

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us